{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:49:39Z","timestamp":1784335779956,"version":"3.55.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T00:00:00Z","timestamp":1749859200000},"content-version":"vor","delay-in-days":164,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.prdoa.2025.100359","type":"journal-article","created":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T18:39:54Z","timestamp":1749926394000},"page":"100359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Bioequivalence of Foslevodopa\/Foscarbidopa continuous subcutaneous infusion to arm, thigh, or flank versus abdomen in healthy and advanced Parkinson\u2019s disease individuals"],"prefix":"10.1016","volume":"13","author":[{"given":"Yi Rang","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanwal","family":"Ayub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly V.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew S.","family":"Kern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Pagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Rosebraugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.prdoa.2025.100359_b0005","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and treatment of Parkinson disease: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.prdoa.2025.100359_b0010","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ncl.2019.12.002","article-title":"Pharmacologic treatment of motor symptoms associated with Parkinson disease","volume":"38","author":"Poewe","year":"2020","journal-title":"Neurol. Clin."},{"issue":"2","key":"10.1016\/j.prdoa.2025.100359_b0015","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2165\/11310940-000000000-00000","article-title":"Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease","volume":"24","author":"Antonini","year":"2010","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.prdoa.2025.100359_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000215875","article-title":"Levodopa: past, present, and future","volume":"62","author":"Hauser","year":"2009","journal-title":"Eur. Neurol."},{"issue":"5","key":"10.1016\/j.prdoa.2025.100359_b0025","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1111\/ene.15734","article-title":"Gastrointestinal barriers to levodopa transport and absorption in Parkinson's disease","volume":"30","author":"Leta","year":"2023","journal-title":"Eur. J. Neurol."},{"issue":"10423","key":"10.1016\/j.prdoa.2025.100359_b0030","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","article-title":"The pathogenesis of Parkinson's disease","volume":"403","author":"Morris","year":"2024","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.prdoa.2025.100359_b0035","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/RLU.0000000000001470","article-title":"Delayed gastric emptying in advanced Parkinson disease: correlation with therapeutic doses","volume":"42","author":"Bestetti","year":"2017","journal-title":"Clin. Nucl. Med."},{"issue":"Suppl 4","key":"10.1016\/j.prdoa.2025.100359_b0040","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00415-008-4006-5","article-title":"Levodopa-induced dyskinesias and their management","volume":"255","author":"Del Sorbo","year":"2008","journal-title":"J. Neurol."},{"issue":"Suppl 11","key":"10.1016\/j.prdoa.2025.100359_b0045","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1002\/mds.20458","article-title":"Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations","volume":"20","author":"Jankovic","year":"2005","journal-title":"Mov. Disord."},{"issue":"23","key":"10.1016\/j.prdoa.2025.100359_b0050","doi-asserted-by":"crossref","DOI":"10.3390\/cells11233736","article-title":"Levodopa-induced dyskinesia in Parkinson's disease: pathogenesis and emerging treatment strategies","volume":"11","author":"Kwon","year":"2022","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.prdoa.2025.100359_b0055","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1517\/14656561003598919","article-title":"Levodopa in Parkinson's disease: from the past to the future","volume":"11","author":"Pezzoli","year":"2010","journal-title":"Expert Opin. Pharmacother."},{"issue":"6","key":"10.1016\/j.prdoa.2025.100359_b0060","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/ana.25364","article-title":"Levodopa-induced dyskinesia in Parkinson disease: current and evolving concepts","volume":"84","author":"Espay","year":"2018","journal-title":"Ann. Neurol."},{"issue":"10423","key":"10.1016\/j.prdoa.2025.100359_b0065","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0140-6736(23)01429-0","article-title":"Medical, surgical, and physical treatments for Parkinson's disease","volume":"403","author":"Foltynie","year":"2024","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.prdoa.2025.100359_b0070","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.2174\/1570159X15666170510143821","article-title":"Levodopa in Parkinson's disease: current status and future developments","volume":"16","author":"Tambasco","year":"2018","journal-title":"Curr. Neuropharmacol."},{"issue":"5","key":"10.1016\/j.prdoa.2025.100359_b0075","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3233\/JPD-225112","article-title":"Infusion therapies in the treatment of Parkinson's disease","volume":"13","author":"van Laar","year":"2023","journal-title":"J. Parkinsons Dis."},{"issue":"6","key":"10.1016\/j.prdoa.2025.100359_b0080","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1007\/s40120-023-00533-1","article-title":"Continuous subcutaneous foslevodopa\/foscarbidopa in Parkinson's disease: safety and efficacy results from a 12-month, single-arm, open-label, phase 3 study","volume":"12","author":"Aldred","year":"2023","journal-title":"Neurol. Ther."},{"issue":"4","key":"10.1016\/j.prdoa.2025.100359_b0085","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.3233\/JPD-212813","article-title":"Foslevodopa\/foscarbidopa is well tolerated and maintains stable levodopa and carbidopa exposure following subcutaneous infusion","volume":"11","author":"Rosebraugh","year":"2021","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.prdoa.2025.100359_b0090","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.parkreldis.2022.03.012","article-title":"Foslevodopa\/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa-carbidopa intestinal gel delivered to the jejunum","volume":"97","author":"Rosebraugh","year":"2022","journal-title":"Parkinsonism Relat. Disord."},{"issue":"1","key":"10.1016\/j.prdoa.2025.100359_b0095","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/ana.26073","article-title":"Foslevodopa\/foscarbidopa: a new subcutaneous treatment for Parkinson's disease","volume":"90","author":"Rosebraugh","year":"2021","journal-title":"Ann. Neurol."},{"issue":"12","key":"10.1016\/j.prdoa.2025.100359_b0100","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S1474-4422(22)00400-8","article-title":"Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial","volume":"21","author":"Soileau","year":"2022","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.prdoa.2025.100359_b0105","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1208\/s12248-012-9439-1","article-title":"Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients","volume":"15","author":"Nyholm","year":"2013","journal-title":"AAPS J."}],"container-title":["Clinical Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112525000635?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112525000635?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T04:51:03Z","timestamp":1772513463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590112525000635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":21,"alternative-id":["S2590112525000635"],"URL":"https:\/\/doi.org\/10.1016\/j.prdoa.2025.100359","relation":{},"ISSN":["2590-1125"],"issn-type":[{"value":"2590-1125","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bioequivalence of Foslevodopa\/Foscarbidopa continuous subcutaneous infusion to arm, thigh, or flank versus abdomen in healthy and advanced Parkinson\u2019s disease individuals","name":"articletitle","label":"Article Title"},{"value":"Clinical Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prdoa.2025.100359","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AbbVie Inc. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100359"}}